A recently developed medication encourages people with cocaine use disorder to reduce their intake of the stimulant – a step ...

Discover how the experimental drug lepodisiran dramatically lowers lipoprotein(a) levels, potentially transforming treatment ...

A single dose of an experimental drug dramatically reduced levels of a deadly form of cholesterol, often thought to be ...

Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a genetically inherited risk ...

In clinical trial results released today, an experimental drug initially developed by Novartis was found to reduce cocaine use in people with cocaine use disorder. Scientists at Novartis led the ...

For the study, the researchers gave the study participants an experimental anti-amyloid drug. They found that 22 participants ...

This development comes at a time when pharmaceutical firms are discontinuing discovery efforts in next-generation COVID-19 ...

Lepodisiran, an experimental drug by Eli Lilly, reduces the risk of genetic heart disease by 94%. The drug significantly decreases Lp(a) levels, a genetically inherited risk for heart attacks and ...

We, like so many others, have been forced to take steps to extend our cash runway,” said Tango’s CEO, citing the “extremely challenging financial markets.” ...

A single dose of an experimental drug dramatically reduced levels of a deadly form of cholesterol, often thought to be untreatable, for up to one year. Lipoprotein(a) is a type of cholesterol that ...